John L. Gollan, M.D., Ph.D., March 3, 1942‐January 6, 2015
Michael F. Sorrell – 18 February 2015
MELDEQ: An alternative Model for End‐Stage Liver Disease score for patients with hepatocellular carcinoma
Michael R. Marvin, Nicole Ferguson, Robert M. Cannon, Christopher M. Jones, Guy N. Brock – 18 February 2015 – Multiple studies have demonstrated an advantage for hepatocellular carcinoma (HCC) patients under the current liver allocation system, such that the United Network for Organ Sharing (UNOS) recently voted in support of a proposal to delay granting Model for End‐Stage Liver Disease (MELD) exception points to all HCC patients for 6 months, independently of a candidate's native MELD score or alpha‐fetoprotein (AFP) level.
Induced pluripotent stem cells model personalized variations in liver disease resulting from α1‐antitrypsin deficiency
Edgar N. Tafaleng, Souvik Chakraborty, Bing Han, Pamela Hale, Wanquan Wu, Alejandro Soto‐Gutierrez, Carol A. Feghali‐Bostwick, Andrew A. Wilson, Darrell N. Kotton, Masaki Nagaya, Stephen C. Strom, Jayanta Roy‐Chowdhury, Donna B. Stolz, David H. Perlmutter, Ira J. Fox – 18 February 2015 – In the classical form of α1‐antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant α1‐antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain‐of‐function, “proteotoxic” mechanism.
Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria
Francis Y. Yao, Neil Mehta, Jennifer Flemming, Jennifer Dodge, Bilal Hameed, Oren Fix, Ryutaro Hirose, Nicholas Fidelman, Robert K. Kerlan, John P. Roberts – 18 February 2015 – We report on the long‐term intention‐to‐treat (ITT) outcome of 118 patients with hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for Organ Sharing T2 criteria before liver transplantation (LT) since 2002 and compare the results with 488 patients listed for LT with HCC meeting T2 criteria at listing in the same period.
Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria
Francis Y. Yao, Neil Mehta, Jennifer Flemming, Jennifer Dodge, Bilal Hameed, Oren Fix, Ryutaro Hirose, Nicholas Fidelman, Robert K. Kerlan, John P. Roberts – 18 February 2015 – We report on the long‐term intention‐to‐treat (ITT) outcome of 118 patients with hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for Organ Sharing T2 criteria before liver transplantation (LT) since 2002 and compare the results with 488 patients listed for LT with HCC meeting T2 criteria at listing in the same period.
Liver transplantation and whipple surgery combined with chemoradiotherapy for treatment of hilar cholangiocarcinoma in patients with primary sclerosing cholangitis
Saman Nikeghbalian, Alireza Shamsaeefar, Ahad Eshraghian, Mohsen Reza Mansoorian, Kourosh Kazemi, Bita Geramizadeh, Seyed Ali Malek‐Hosseini – 17 February 2015
Reply
Ho Cheol Hong, Kyung Mook Choi – 17 February 2015
The safety and efficacy of proximal splenic artery embolization after liver transplantation are still not clearly defined
Garrett R. Roll, Paolo Muiesan – 17 February 2015
Urea production during normothermic machine perfusion: Price of success?
Janske Reiling, David S. R. Lockwood, Andrew H. Simpson, Catherine M. Campbell, Kim R. Bridle, Nishreen Santrampurwala, Laurence J. Britton, Darrell H. G. Crawford, Cornelius H. C. Dejong, Jonathan Fawcett – 17 February 2015
Macrosteatotic and nonmacrosteatotic grafts respond differently to intermittent hepatic inflow occlusion: Comparison of recipient survival
Sangbin Han, Gyu‐Seong Choi, Jong Man Kim, Ji Hye Kwon, Hyo‐Won Park, Gaabsoo Kim, Choon Hyuck David Kwon, Mi Sook Gwak, Justin Sangwook Ko, Jae‐Won Joh – 17 February 2015 – Intermittent hepatic inflow occlusion (IHIO) during liver graft procurement is known to confer protection against graft ischemia/reperfusion injury and thus may benefit the recipient's outcome. We evaluated whether the protective effect of IHIO differs with the presence of macrosteatosis (MaS) and with an increase or decrease in the cumulative occlusion time.